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Longitudinal analysis of safety 
and medication adherence 
of patients in the Fingolimod 
patient support program: 
a real‑world observational study
Aline Bourdin 1,2,3*, Marie Paule Schneider 2,3, Isabella Locatelli4, Myriam Schluep5, 
Olivier Bugnon 1,2,3 & Jérôme Berger 1,2,3
The Fingolimod Patient Support Program (F‑PSP) is an interprofessional specialty pharmacy service 
designed to ensure responsible use of fingolimod by promoting patient safety and medication 
adherence. This study aims to evaluate the safety and medication adherence of patients who joined 
the F‑PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety 
data (patient‑reported symptoms, discontinuations due to adverse events (AEs), repeated first‑dose 
monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, 
influence of covariates, barriers and facilitators) were described. Sixty‑seven patients joined the 
F‑PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued 
fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients 
repeated the first‑dose monitoring. Patients had a high medication adherence over the 18‑month 
analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 
83.2% at 18 months. The patients’ level of education, professional situation, and living with child(ren) 
influenced implementation. Patients reported more facilitators of medication adherence than barriers. 
The F‑PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod 
and inviting patients for shared‑decision making) and public health (indirectly gathering real‑world 
evidence).
Fingolimod is an oral disease-modifying therapy (DMT) that was approved as a first-line drug for relaps-
ing–remitting multiple sclerosis (MS) in the USA, Switzerland, and Australia. Pharmacovigilance measures are 
mandatory due to safety issues such as cardiovascular, ophthalmic, hematologic, hepatic, or pulmonary complica-
tions and risk of infections, cancer, and fetal  toxicity1. Six hours of medical monitoring for bradycardia is required 
immediately after administration of the first dose, and various other medical tests are recommended prior to 
and after treatment initiation. Patients should be warned about the symptoms of potential serious adverse events 
(AEs), and women of childbearing potential should be informed about the teratogenic risk and use of effective 
 contraception2. Moreover, chronic drug intake is  challenging3. Optimal DMT adherence is associated with a 
decreased risk of relapses and medical  costs4,5. Therefore, support of patients taking fingolimod is  encouraged2,4.
In 2013, the Community Pharmacy of the University Center for Primary Care and Public Health, Lausanne 
(Switzerland), and the MS clinic of the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois—
CHUV), launched and disseminated in a pharmacy network an interprofessional specialty pharmacy service: 
the Fingolimod Patient Support Program (F-PSP)6. The F-PSP aims to ensure responsible use of fingolimod and 
empowerment of patients by promoting patient safety and medication adherence through a person-centered and 
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integrated care approach. It consists of regular pharmacist-led motivational interviews supported by a secure 
web platform (from SISPha SA), which includes a clinical decision aid system, patient health records, and a 
data collection system (recording, e.g., patient administrative data, adherence data, patient-reported outcomes). 
Patient safety is ensured through pharmacovigilance activities by informing patients regarding the responsible 
use of fingolimod (e.g., missed dose management, active contraception, co-treatment management), remind 
them about recommended medical tests, and track and monitor patient-reported symptoms (especially those 
who would signal potential serious adverse fingolimod reactions). Fingolimod adherence is monitored by an 
electronic monitor (EM) (MEMS SmartCap, Aardex Group). The cap of the EM bottle in which fingolimod is 
supplied records each opening and displays it on an LCD screen as a real-time reminder for patients. At the 
pharmacy, EM data are uploaded onto a secure website. Patient intake data are displayed on a graph, which is 
used by the pharmacist to give feedback to the patients during each interview. To mitigate the risk of bias linked 
to EM use, its use is validated prior to each interview by a pill count and by asking patients whether fingolimod 
has ever been taken without EM (e.g., pocket doses). During interviews, barriers to and facilitators of medica-
tion adherence identified by pharmacists are recorded on the SISPha-platform. At the end of each interview, the 
platform issues a structured report, which is available to the patient’s neurologist, MS nurse, general practitioner, 
and/or other pharmacists to ensure continuity of care.
The F-PSP is disseminated throughout Western Switzerland through a trained pharmacy network (22 pharma-
cies, including the Pharmacy of Unisanté). Participation in the F-PSP is proposed during the first-dose monitor-
ing to each patient starting fingolimod at the MS clinic. Patients are free to join in any network pharmacy and 
can withdraw at any time.
This study aims to evaluate the safety and medication adherence of patients participating in the F-PSP during 
the first three years post-implementation.
Methods
The cantonal commission for the ethics of human research (Commission cantonale d’éthique de la recherche sur 
l’être humain du canton de Vaud—CER-VD) approved this observational study (2016–00328) and informed 
consent to participate in the study was obtained from all participants. This study was performed in accordance 
with that Ethics Committee relevant guidelines and regulations. The included population consisted of MS patients 
starting fingolimod and joining the F-PSP between October 2013 and October 2016.
Patient sociodemographic and medical characteristics. Sociodemographic data were collected 
using a 6-item questionnaire. Medical data were extracted retrospectively from the records of the MS clinic. 
The sociodemographic and medical characteristics of F-PSP patients at the time of fingolimod initiation were 
compared to those of patients who did not join the F-PSP. Two-tailed Student’s t tests were used to compare data 
with normal distributions, and the Wilcoxon–Mann–Whitney test was applied for non-normally distributed 
data. Fisher’s exact test and the chi-square test were used to test for differences in categorical variables. Statisti-
cal significance was set at p < 0.05. Analyses were performed with Stata version 15.0 (StataCorp, College Station, 
Texas).
Patient safety. Patient safety was assessed over the 3-year F-PSP observation period (2013–2016). Patient-
reported symptoms during repeated F-PSP interviews and the level of discomfort assessed by patients were 
extracted from the SISPha-platform. A symptom was defined as a subjective experience reported by the  patient7. 
The most frequent symptoms were those reported by ≥ 10% patients, a cutoff commonly used in drug monog-
raphies.
The repeated first-dose monitoring was established based on the medical records and was recorded on the 
SISPha-platform.
Medication adherence. Adherence was operationalized through the definitions of implementation and 
persistence as described by the ABC taxonomy. Implementation is defined as “the extent to which a patient’s 
actual dosing corresponds to the prescribed dosing regimen, from initiation until the last dose is taken”8. Imple-
mentation on day D is the probability of taking (at least) all prescribed doses on day D for a subject who is still 
persistent on that  day9. Persistence is the time between initiation and discontinuation of the  treatment8. Persis-
tence on day D is the probability of not yet having discontinued on day  D9. Discontinuation is either a unilateral 
patient decision or a physician–patient joint decision (e.g., AEs, ineffectiveness or pregnancy). Adherence on 
day D is the probability of taking at least all prescribed doses on day D (for a patient who entered the F-PSP)9. 
Implementation and persistence were modelled longitudinally using EM data.
Data validation. EM raw data were extracted from the SISPha-platform and validated in sets. A data set 
included all opening dates, which occurred between two consecutive F-PSP interviews. Each data set was vali-
dated by calculating the absolute difference (ABS) between the electronic drug monitoring-based proportion of 
prescribed doses taken (%EDM) and pill count-based proportion of prescribed doses taken (%PC) for each inter-
visit period as follows: ABS (%EDM—%PC)10. Set data were considered as valid if the difference was < 25%. This 
cutoff was defined based on the experience of the  group11,12; a higher difference would substantially decrease the 
validity of the adherence measure. If it was ≥ 25%, the %EDM was recalculated by including periods of pocket 
dosing reported by the patient. If the difference was still ≥ 25%, %EDM and %PC were recalculated by merging 
the following intervisit period. If that was not possible, the %EDM was compared with the previously validated 
%EDM and was considered valid when the difference was within a range of ± 10%. Data sets with a ≥ 25% differ-
ence were excluded from the analysis.
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Data analysis. The longitudinal analysis was performed over the first 18 months of treatment, defined by the 
median observation time (from fingolimod initiation to the last EM opening) to ensure sufficient data for a 
reliable analysis. Each pocket dose was considered a missing value. Openings made from midnight to 2 h 59 
were considered to belong to the previous day. Extra daily openings were ignored. Short breaks (≤ 1.5% of total 
days—arbitrary cut-off of individual total monitored days) in treatment prescribed by the neurologist (due to 
AEs) were considered missing values. In cases of long breaks, only the first data sets were analyzed and patients 
were considered to have stopped treatment according to a physician–patient joint decision on the date of the 
beginning of the break.
Implementation was computed at each day D as the proportion of patients taking fingolimod as prescribed 
among the persistent patients and not censored on day D. Patients were censored if they withdrew from the 
F-PSP before the end of the analysis period but continued taking fingolimod. A logistic generalized estimating 
equation model (exchangeable correlation) was used to estimate the implementation over time using polynoms 
of time as covariates. Persistence was represented by a Kaplan–Meier curve, which estimates the probability of 
being persistent on each day D, taking into account censoring durations. Adherence was calculated on each day 
D as the product between implementation and persistence, representing the probability of taking at least the 
prescribed dose on day  D9.
Covariate influence. The influence of covariates on implementation was assessed using univariate adjusted 
analyses. The covariates, measured at fingolimod initiation, were age (< 35/ ≥ 35 years), gender (men/women), 
level of education (low (primary and secondary levels)/high (tertiary level)), professional situation (active/inac-
tive), living with child(ren) (yes/no), previous DMT (yes/no) and disease activity (≤ 1/ > 1 relapse).
Reasons for discontinuation. Reasons for discontinuation were identified based on the information rec-
onciled by the SISPha-platform and the medical records. Barriers to and facilitators of adherence were extracted 
from the SISPha-platform. Both outcomes were assessed over the 3-year F-PSP observation period (2013–2016).
Results
From October 2013 to October 2016, 116 patients started fingolimod at the CHUV and were seen by a pharma-
cist for inclusion in the F-PSP; 58% (67/116) patients voluntarily joined the program in 11 network pharmacies 
(Fig. 1). Questions asked by patients during the F-PSP presentation are presented in the Additional file.
Over this 3-year period, pharmacists conducted 553 F-PSP interviews with the 67 patients, with an average 
(mean ± standard deviation) of 8.3 ± 4.2 interviews/patient. The median patient retention time in the F-PSP was 
11 months (interquartile rage (IQR): 6–19)).
Figure 1.  F-PSP status and number of patients over the 3-year observation period (Oct. 13 to Oct. 16); CHUV: 
Centre Hospitalier Universitaire Vaudois (Lausanne University Hospital); AE: adverse event; F-PSP: Fingolimod 
Patient Support Program; MS: multiple sclerosis.
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Patient sociodemographic and medical characteristics. Table 1 presents the patients sociodemo-
graphic and medical characteristics. No differences in sociodemographic characteristics were observed between 
the F-PSP patients and those who did not join the F-PSP. However, differences were observed regarding the 
medical characteristics: F-PSP patients had a significantly higher annualized relapse rate before fingolimod ini-
tiation, a shorter disease duration, and no previous DMT compared with patients who did not join the F-PSP.
Patient safety. The 67 patients reported 965 symptoms (97% of patients reported any symptoms), 56% were 
assessed as mild, 32% moderate, and 11% major discomfort (10% missing values). Table 2 presents the most 
frequently reported symptoms.
Forty-four (66%) patients reported at least one symptom classified as one of the most common AEs (influenza 
viral infections, headaches, coughing, diarrhea or back pain) of fingolimod. Table 2 summarizes the number of 
patients who reported symptom(s) of a potential serious adverse fingolimod reaction.
Table 3 describes the consequences of AEs and the number of patients who had to repeat the first-dose 
monitoring plan after a treatment break.
Medication adherence. EM data were validated for 50/67 (75%) patients. Validation could not been per-
form in 16 patients because pill count values were missing throughout their follow-up. Additionally, half of the 
EM data was invalid for another patient despite the reconciliation process. According to reports from the F-PSP 
interviews, the latter did not use the EM systematically. Therefore, this patient was excluded from the adherence 
analysis. In addition, the data set of one intervisit period (127 days) for one patient was not valid, and these data 
were considered missing values.
Table 1.  Sociodemographics and medical characteristics of F-PSP patients and of patients who did not join 
the F-PSP at the time of fingolimod initiation. AAR: annualized relapse rate; DMT: drug modified therapy; 
EDSS: Expanded Disability Status Scale; IQR: interquartile range; n: number; SD: standard deviation. aNine 
patients could not be interviewed with the sociodemographic questionnaire and 1 refused it; bFor example, 
stay-at-home parents, students, unemployed, retired, disability insurance, on maternity leave; cEight patients 
did not give consent to access their medical records; dChi-square test; eStudent’s t-test; fFisher’s exact 
test; gWilcoxon–Mann–Whitney test.
All F-PSP patients Patients not joining F-PSP P
Patients—n (%) 116 (100) 67 (58) 49 (42)
Female—n (%) 76 (66) 42 (63) 34 (69) 0.453d
Male—n (%) 40 (34) 25 (37) 15 (31)
Age, years—mean (SD) 38 (12) 37 (12) 39 (11) 0.292e
Sociodemographic dataa 106 (91) 62 (93) 44 (90)
Level of education—n (%) 2 missing values
Primary level 8 (8) 5 (8) 3 (7)
0.867fSecondary level 47 (45) 26 (43) 21 (49)
Tertiary level 49 (47) 30 (49) 19 (44)
Professional situation—n (%)
Working 74 (70) 43 (69) 31 (70) 0.842f
Not  workingb 32 (30) 19 (31) 13 (30) 0.903d
Activity of working patients—n (%)
Full-time (100%) 35 (47) 21 (49) 14 (45)
0.755d
Part-time (< 100%) 39 (53) 22 (51) 17 (55)
Home situation—n (%)
Alone 21 (20) 10 (16) 11 (25)
0.532f
With a partner 64 (60) 37 (60) 27 (61)
With parent(s) 14 (13) 10 (16) 4 (9)
With roommate(s) 7 (7) 5 (8) 2 (5)
Living with child(ren)—n (%) 1 missing value
Yes 48 (46) 27 (44) 21 (48)
0.725d
No 57 (54) 34 (56) 23 (52)
Medical datac 108 (93) 66 (99) 42 (86)
EDSS—median (IQR) 1.5 (1.5–2.0) 1.5 (1.5–2.0) 1.5 (1.5–2.4) 0.772g
ARR before fingolimod initiation—median (IQR) 0.6 (0.3–1.5) 0.8 (0.4–2.1) 0.5 (0.3–0.8) 0.018g
Months since diagnosis—median (IQR) 24 (4–69) 8 (3–42) 47 (19–116)  < 0.001g
Previous DMT—n (%)
Yes 55 (51) 25 (38) 30 (71)
0.001d
No 53 (49) 41 (62) 12 (29)
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A sensitivity analysis of patients with validated EM data vs those with unvalidated data showed no difference 
between the two groups, which allowed for data pooling (50 plus 16 patients) for the analyses.
Implementation (95%CI) decreased over time, from 98.8% (97.7%–99.3%) at initiation to 93.7% (89.9–96.1%) 
at 18 months (Fig. 2A). Figure 2B shows that 83.2% (73.7%—94.0%) of the patients were still persistent after 
18 months of treatment.
Over the 3-year period of F-PSP observation, 11 (16%) patients discontinued fingolimod: 10 (91%) based on 
physician–patient joint decisions, and one (9%) according to a unilateral patient decision. Table 4 presents the 
reasons for fingolimod discontinuation and switching to other DMTs.
Table 2.  Most frequent symptoms reported by ≥ 10% patients (n = 67) during the F-PSP interviews (n = 553) 
and number of patients who reported symptom(s) of a potential serious adverse fingolimod reaction from 
2013 to 2016. n: number. aAt least two cumulative symptoms: fatigue; nausea; vomiting; fever; joint/muscular 
pain; shivering; herpes; shingles; bAt least one of the following symptoms: blurred, distorted, or veiled vision; 
shaded or black spot in the center of vision; hypersensitivity to light; change in color perception; cAt least two 
cumulative symptoms: fatigue; dizziness; palpitations; dAt least two cumulative symptoms: fatigue; nausea; 
vomiting; epigastric pain; loss of appetite; yellow skin or eyes; dark urine; eBreathing disorders.
Patients n (%) Interviews n (%)
Any symptom reported 65 (97) 348 (63)
Most frequent symptoms reported by ≥ 10% patients
 Fatigue 48 (72) 205 (37)
 Dizziness 32 (48) 71 (13)
 Headaches 32 (48) 78 (14)
 Joint/muscular pain 30 (45) 69 (12)
 Blurred or distorted or veiled vision 28 (42) 62 (11)
 Palpitations 22 (33) 41 (7)
 Diarrhea 17 (25) 33 (6)
 Nausea 16 (24) 34 (6)
 Epigastric pain 16 (24) 29 (5)
 Breathing disorders 16(24) 27 (5)
 Coughing 16 (24) 23 (4)
 Hypersensitivity to light 15(22) 28 (5)
 Back pain 13 (19) 21 (4)
 Influenza Viral Infections 12 (18) 15 (3)
 Dark urine 10 (15) 16 (3)
 Shivering 10 (15) 15 (3)
 Loss of appetite 9 (13) 15(3)
 All other infections 9 (13) 12 (2)
 Vomiting 7 (10) 11 (2)
Potential serious adverse fingolimod reactions
 Infectionsa 39 (58) –
Macular  edemab 37 (55) –
 Cardiovascular disorder  eventsc 35 (52) –
 Hepatic disorder  eventsd 31(46) –
 Pulmonary disorder  eventse 16 (24) –
Table 3.  Adverse event consequences and repeated first-dose monitoring (n = 67 patients). AEs: adverse 
events; EOD: every other day; n: number.
Patients n (%) Timing (in months) and length (in days)
AEs consequences
 Fingolimod discontinuation due to AEs 7(10) 2nd, 4th, 8th [2 patients], 13th [2 patients], 20th
 Fingolimod breaks 3 (4) 4th (8 days), 10th (104 days), 23rd (77 days)
 Fingolimod regimen reduced to EOD 1 (1) 7th (31 days)
Repeated 1st dose monitoring
 Following fingolimod break 2 (3) 13th, 26th
 Following haphazard drug intake 1 (1) 6th
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Level of education, professional situation, and living with child(ren) influenced implementation, but the 
other tested variables did not (Fig. 3). Fingolimod implementation of patients with a high level of education or 
who were professionally active decreased over time, while time had no influence on the implementation of less 
educated or professionally inactive patients (straight line in Fig. 3A,B). Patients living with child(ren) had higher 
implementation than patients living without child(ren) over the entire time period.
All F-PSP patients had at least one facilitator of adherence during their follow-up, and 76% of patients had 
at least one barrier. The main facilitators of each single following category were as follows: drug intake schedule 
(97% patients) as a treatment-related factor, good understanding of the treatment (94%) in a psycho-cognitive 
Table 4.  Reasons for fingolimod discontinuation and switching to other DMTs (n = 67 patients). DMT: drug 
modified therapy; IFN: interferon; n: number; SC: subcutaneous; aTwo patients were lost to follow-up after 
discontinuation, so information on the switch is missing.
Patients n (%) Timing (in months)
Reasons for discontinuation 11 (16)
Adverse events 7 (64) 2nd, 4th, 8th [2 patients], 13th [2 patients], 20th
Pregnancy planning 2 (18) 11th, 20th
Lack of effectiveness 1 (9) 25th
Unilateral patient decision 1 (9) 6th
Switchesa 7 (64)
Dimethyl fumarate 3 (27) 7th, 16th, 25th
Natalizumab 3 (27) 12th, 20th, 25th
INF-Bêta1a SC 1 (9)  9th
Figure 2.  (A) Implementation among patients taking fingolimod and number of participants over 18 months, 
and (B) Persistence and adherence estimations among patients taking fingolimod over 18 months.
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4107  | https://doi.org/10.1038/s41598-021-83220-1
www.nature.com/scientificreports/
factor, and social support (77%) as a socio-economic factor. The main barriers of each category were the drug 
intake schedule (21%), anxiety (33%), and an unstructured lifestyle (33%), respectively (Fig. 4).
Discussion. This study assessed the safety and medication adherence of 67 patients taking fingolimod who 
entered the F-PSP. The sociodemographic characteristics of those patients were similar to those who did not join 
the program. However, DMT-naïve patients with high annualized relapse rates and short disease durations were 
more likely to join the program than their counterparts. Thus, the patients most likely to accept this program 
were those in a more acute situation of their disease and/or at a time just after diagnosis of their disease and/or 
receiving their first treatment.
Almost all patients reported at least one symptom during their F-PSP follow-up. The proportion of patients 
who reported symptoms were higher than those documented in clinical  trials13,14 and other real-world clinical 
practice  studies15–18. Compared with the rates reported in clinical trials, blurred vision occurred greater than ten 
times more frequently, fatigue and dizziness more than six times, and diarrhea and headaches more than two 
 times1,13,14. More than half of the patients reported symptoms of potential serious adverse fingolimod reactions: 
infections, macular edema, and cardiovascular disorder events. However, symptoms reported are probably not all 
due to these serious adverse reactions; medical exams should be performed to confirm such diagnosis. Patients 
reported symptoms more frequently than in other real-world clinical practice studies, most likely because the 
Figure 3.  Influence of the level of education (A), professional situation (B), and living with child(ren) (C) on 
implementation by patients taking fingolimod.
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F-PSP interviews focus on patients’ experiences, concerns, and beliefs. They were not objectified by a physician or 
a medical test. In addition, our data were from a pharmacy-based patient support program, with more frequent 
visits than those to the physician; thus, the patients are more likely to remember all their symptoms.
AEs resulted in fingolimod discontinuation in 10.4% of the study sample over a wide range of months 
(min–max: 2nd-20th with the majority within the first 13 months). This latter finding is inferior to those reported 
in Hersh et al. (13.1% over 12 months of follow-up)16 and Arichon et al. (16.4% over 12 months of follow-up)18, 
but superior to those in clinical  trials13,14 and other real-world clinical practice  studies19–22. The ability to make 
comparisons among these studies is limited because the majority had a shorter follow-up period than our study. 
Some studies focused on experienced patients (with at least 12 months of treatment), hence excluding those who 
could have discontinued fingolimod within the first year of treatment. AEs have drove 4.5% of fingolimod breaks, 
of which 2/3 led to repeated first-dose monitoring. Similarly to our results, in a large real-world clinical practice 
study assessing 2399 patients attending an educational support program (reinforcing adherence to medical 
tests but not to fingolimod), 3.9% of patients repeated the first-dose monitoring following a therapeutic  break23.
Implementation was high but decreased over time (from 98.8 to 93.7%). This high implementation can be 
ascribed to the tailored support provided by the program. Indeed, tools for self-monitoring, EM-feedback, and 
cognitive-educational interventions focused on supplying patients with knowledge, counseling, and accountabil-
ity (all of which are F-PSP core elements) to positively influence medication  adherence24–26. Another real-world 
study investigated fingolimod implementation (generalized estimating equation analysis using pill count data 
reconciled with refill data and periods of pocket dosing) in 98 patients over 2  years27. The mean estimated imple-
mentation rate was 98.6% (95% CI 98.5–98.7), and it was stable over time. This result was similar at 18 months, 
which is slightly higher than ours. This minor difference may be explained by the different measurement methods 
because nonelectronic measures may overestimate medication  adherence28.
Our 18-month estimated persistence of 83.2% F-PSP patients is consistent with the results of a meta-analysis 
(25 real-world studies), which estimated the persistence rate of fingolimod as 82% (95% CI 79–85) at 1  year29. This 
finding is also in line with clinical trials (81.2% after 2 years)13 and with a phase IV trial (81.3% after 48 weeks)30.
Most fingolimod discontinuations (91%) were based on a physician–patient joint decision over the 3-year 
F-PSP observation period. Zimmer et al. reported a similar finding (89.5% in 98 patients followed over 2 years)27. 
Physician–patient joint decisions regarding discontinuation among patients attending the F-PSP were mainly 
associated with AEs, followed by pregnancy planning and ineffectiveness. Ineffectiveness and AEs were also the 
main reasons for discontinuing fingolimod cited by a systematic review based on real-world  studies31.
Level of education, professional situation, and living with child(ren) influenced fingolimod implementation. 
Although the literature describes positive associations between adherence, education, and health literacy, our 
results add nuances to these  findings32. Indeed, the implementation in this subgroup decreased over time, which 
was opposite to the trend observed in patients with lower levels of education. A hypothesis is that patients with 
a high level of education are likely to take progressive liberties in drug intake, realizing that occasional missed 
doses over time are inconsequential. Further investigations must investigate this finding.
Figure 4.  Facilitators of and barriers to fingolimod adherence by F-PSP patients.
9
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4107  | https://doi.org/10.1038/s41598-021-83220-1
www.nature.com/scientificreports/
While the structured lifestyle provided by patients’ professional activity seems to positively influence medica-
tion adherence in the early stages, the positive effect vanishes with time. Notably, this finding should be cautiously 
interpreted due to the unbalanced proportions of patients in the two subgroups.
Implementation was higher in patients living with child(ren). The presence of child(ren) may provide a more 
organized routine and structured lifestyle, facilitating drug intake. Moreover, children are probably a substantial 
source of motivation to take fingolimod with the hope to stabilize the disease over the long-term.
F-PSP patients reported a larger number of facilitators of fingolimod adherence than barriers, which cor-
roborates the group’s high level of medication adherence. Anxiety was the factor most frequently identified by 
pharmacists as a barrier to taking fingolimod, which is known to be a burden for MS  patients33.
One of the most substantial strengths of this study is the joint provision of relevant information regard-
ing the safety and medication adherence of patients taking fingolimod in a real-world setting. Postmarketing, 
patient-reported data are needed to validate clinical trial findings in larger and unselected populations. Another 
strength is the longitudinal adherence assessment by EM measurement, which is considered the gold standard 
for measuring implementation  accurately34. The 18-month median observation period of longitudinal data is 
longer than in most studies. In addition, the reconciliation of EM data with pill count data and periods of pocket 
dosing validated by the patients increases the reliability of the  results34. The use of a persistence model includ-
ing censures is another strength. The main limitation is the observational and retrospective nature of the study. 
In the absence of a control group, no inference can be drawn from it; the effectiveness or impact of the F-PSP 
could not be demonstrated. This should be the subject of another study, where participants would be observed 
over a same period of time and where adverse events would be collected similarly from patients in and out of 
the program. Generalization to the MS population is limited because we cannot infer that patients attending 
a support program are similar to the entire MS population. Patients attending the program probably repre-
sent the population who is more in need of support for initiating a treatment for the very first time. However, 
healthcare professionals should not miss experienced patients who have difficulties adhering to their treatment. 
Special attention should be provided to them to include them in such a program. In addition, AE imputation of 
patient-reported symptoms was not assessed; these were patients’ perceptions, which may not be associated with 
fingolimod. Finally, the validation of one-third of the EM data could not be performed because EM use was not 
sufficiently documented in some network pharmacies.
Conclusion
The pharmacy-based F-PSP, with a pharmacovigilance activity in tracking patient-reported symptoms and 
monitoring of medication adherence, has an interest in supporting individual patients, ensuring responsible 
use of drugs, and an interest in public health, gathering valuable real-world evidence. The high frequency of 
patient-reported symptoms, including a few potential serious adverse fingolimod reactions, and the various AE 
consequences, highlight the importance of regular and repeated patient support over time. Symptoms, as subjec-
tive experiences perceived by patients, show the need to reassure patients and answer their questions. Moreover, 
F-PSP patients had high fingolimod implementation and persistence. The strengthening of medication adherence 
through this type of interprofessional program (pharmacist, neurologist, MS nurse, general practitioner) might 
eventually improve the therapeutic effect and reduce frequency of medical consultations. Pharmacovigilance and 
medication adherence monitoring have the potential to positively influence the overall cost of care per patient. 
All these findings favor expanding the dissemination of the F-PSP to other pharmacist-physician collaborations 
and to more patients starting fingolimod. Finally, the F-PSP should serve as a model for other specialty drugs, 
diseases, or healthcare contexts. To achieve this goal, further research in implementation science with more 
patients and interprofessional collaborations is needed, in conjunction with sound cost-effectiveness analyses.
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